Consequently, while current studies about tumor immunity have primarily focused on CD8+ T cells and tumor cells, especially in OSCC, a more comprehensive understanding that is not confined to these cell types is crucial for more robust development of cancer immunotherapy. This evidence concerns the gene CD8A and cancer.